Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.

Related Videos
Nathalie McDowell Johnson, MD, FACS
Expert on urothelial carcinoma
Expert on urothelial carcinoma
William M. Sikov, MD
Experts on CSCC
Expert on CSCC
Experts on prostate cancer
Experts on prostate cancer
Experts on CRC
Expert on CRC
Related Content